AGENAgenus Inc.Running, no new patients
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 234 (final count)
- Started
- Nov 30, 2022
- Main results expected
- Sep 2027
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate
Measured over: First dose through up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05608044 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC